Chemical Biological Defense Acquisition Initiatives Forum (CBDAIF)

MEDICAL COUNTERMEASURES (MCM) SECTOR REPORT

07 February 2018

Presented by Sector Representative, Pam Duchars
Companies in Sector

• Big Pharma
  – Examples are Janssen, Sanofi, GSK, Merck, and Pfizer

• Specialty Pharma
  – Examples are Emergent Biosolutions, Bavarian Nordic and Ology

• Small Companies
  – Examples are Profectus, Kineta, AktiVax and Mapp Pharmaceuticals

• CMOs
  – Examples are ABL and Fujifilm Pharmaceuticals,

• CROs
  – PPD, IITRI, SRI

• Non-profits
  – Examples are Battelle, MRI Global, SwRI, and CUBRC

• Consultants
  – Examples are Latham, Tiber Creek, and SMI

• There are 144 members in the MCDC Consortium at this point in time
MCM Sector Health

• **Current Health**
  – Medical Countermeasure Sector capability to support DoD and others remains relatively strong in certain areas where there is a synergistic commercial need like infectious disease and weaker in other areas such as chemical and radiological

• **Future Health**
  – Medical Countermeasure Sector capabilities remain threatened due to lack of clarity on future business opportunities, lack of clarity on funding, unexpected shifting of funds, lack of coordination between agencies, lack of granularity on procurement volumes, lack of other incentives beyond sales

• **Notable**
  – Some of Pharma has given strong indications (Sanofi, GSK, Merck) of exiting from the emerging infectious disease arena after Zika and Ebola
Major Sector Concerns

• Shifting funds make it difficult to align with programs and priorities (BDTX Antiviral RPP example)

• Lack of understanding of differences between DARPA and PRISM programs such as P3 and the upcoming Antibody RPP

• Better definition of what it means to be in MCDC basket

• Continued lack of alignment amongst the agencies for similar or same products
  – Applies to within DOD, though many remarked it is getting better between JSTO and MCS
  – Between DoD and HHS
Other Sector Issues

• ADM viewed as potentially competing organization and seems conflicting to some organizations

• Confusion regarding cost share guidance for Non-traditionals versus Non-profits

• Request updated plans to industry on where JPEO is now going (i.e. 5 yr and 30 yr plans)

• Small companies are still finding the volume and timing of proposals between and amongst agencies to be difficult to manage
Positive Feedback

• Priority review vouchers have been well received
• Speed of contracting and open dialogue within the MCDC Consortium has been welcomed
• PRISM looks exciting to many industry players
• Non-profits are thrilled with the change in the OTA regulations